Growth hormone treatment for growth failure in pediatric patients with Crohn's disease.

摘要: Objective To investigate the effect of human growth hormone (GH) injections on velocity in growth-impaired children with Crohn's disease (CD). Study design Ten and adolescents (mean age, 12.6 ± 4.5 years; 6 males) CD poor height were treated open-label recombinant GH, 0.043 mg/kg/day administered via subcutaneous injection, for 1 year. Patients retrospectively matched untreated patients (3 comparisons per case) by race, sex, baseline height. Primary endpoint was velocity; secondary endpoints activity, body composition, bone density determined dual-energy x-ray absorptiometry scan. Results Mean increased 5.33 3.40 standard deviation) cm/year GH-treated during year GH treatment, compared 0.96 3.52 comparison group ( P = .03). Height z -score 0.76 0.38 group, 0.16 0.40 0.81 0.89 0.00 0.57 .03 vs baseline). Conclusions treatment increases may enhance mineralization CD. A randomized controlled trial a large cohort is needed to evaluate ultimate impact treatment.